A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer
Jessie Qiaoyi Liang, Tong Li, Geicho Nakatsu, Ying-Xuan Chen, Tung On Yau, Eagle Chu, Sunny Wong, Chun Ho Szeto, Siew C Ng, Francis K L Chan, Jing-Yuan Fang, Joseph J Y Sung, Jun Yu, Jessie Qiaoyi Liang, Tong Li, Geicho Nakatsu, Ying-Xuan Chen, Tung On Yau, Eagle Chu, Sunny Wong, Chun Ho Szeto, Siew C Ng, Francis K L Chan, Jing-Yuan Fang, Joseph J Y Sung, Jun Yu
Abstract
Objective: There is a need for early detection of colorectal cancer (CRC) at precancerous-stage adenoma. Here, we identified novel faecal bacterial markers for diagnosing adenoma.
Design: This study included 1012 subjects (274 CRC, 353 adenoma and 385 controls) from two independent Asian groups. Candidate markers were identified by metagenomics and validated by targeted quantitative PCR.
Results: Metagenomic analysis identified 'm3' from a Lachnoclostridium sp., Fusobacterium nucleatum (Fn) and Clostridium hathewayi (Ch) to be significantly enriched in adenoma. Faecal m3 and Fn were significantly increased from normal to adenoma to CRC (p<0.0001, linear trend by one-way ANOVA) in group I (n=698), which was further confirmed in group II (n=313; p<0.0001). Faecal m3 may perform better than Fn in distinguishing adenoma from controls (areas under the receiver operating characteristic curve (AUROCs) m3=0.675 vs Fn=0.620, p=0.09), while Fn performed better in diagnosing CRC (AUROCs Fn=0.862 vs m3=0.741, p<0.0001). At 78.5% specificity, m3 and Fn showed sensitivities of 48.3% and 33.8% for adenoma, and 62.1% and 77.8% for CRC, respectively. In a subgroup tested with faecal immunochemical test (FIT; n=642), m3 performed better than FIT in detecting adenoma (sensitivities for non-advanced and advanced adenomas of 44.2% and 50.8% by m3 (specificity=79.6%) vs 0% and 16.1% by FIT (specificity=98.5%)). Combining with FIT improved sensitivity of m3 for advanced adenoma to 56.8%. The combination of m3 with Fn, Ch, Bacteroides clarus and FIT performed best for diagnosing CRC (specificity=81.2% and sensitivity=93.8%).
Conclusion: This study identifies a novel bacterial marker m3 for the non-invasive diagnosis of colorectal adenoma.
Keywords: colonic bacteria; colorectal adenomas; colorectal cancer screening.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Allemani C, Matsuda T, Di Carlo V, et al. . Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–75. 10.1016/S0140-6736(17)33326-3
- The Lancet GLOBOCAN 2018: counting the toll of cancer. Lancet 2018;392:985 10.1016/S0140-6736(18)32252-9
- Irrazábal T, Belcheva A, Girardin SE, et al. . The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 2014;54:309–20. 10.1016/j.molcel.2014.03.039
- Yu J, Feng Q, Wong SH, et al. . Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 2017;66:70–8. 10.1136/gutjnl-2015-309800
- Nakatsu G, Li X, Zhou H, et al. . Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 2015;6:8727 10.1038/ncomms9727
- Dai Z, Coker OO, Nakatsu G, et al. . Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome 2018;6 10.1186/s40168-018-0451-2
- Tilg H, Adolph TE, Gerner RR, et al. . The intestinal microbiota in colorectal cancer. Cancer Cell 2018;33:954–64. 10.1016/j.ccell.2018.03.004
- Wong SH, Zhao L, Zhang X, et al. . Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology 2017;153:1621–33. 10.1053/j.gastro.2017.08.022
- Kostic AD, Chun E, Robertson L, et al. . Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013;14:207–15. 10.1016/j.chom.2013.07.007
- Rubinstein MR, Wang X, Liu W, et al. . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14:195–206. 10.1016/j.chom.2013.07.012
- Yu T, Guo F, Yu Y, et al. . Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017;170:548–63. e16 10.1016/j.cell.2017.07.008
- Tsoi H, Chu ESH, Zhang X, et al. . Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology 2017;152:1419–33. 10.1053/j.gastro.2017.01.009
- Liang Q, Chiu J, Chen Y, et al. . Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res 2017;23:2061–70. 10.1158/1078-0432.CCR-16-1599
- Xie Y-H, Gao Q-Y, Cai G-X, et al. . Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine 2017;25:32–40. 10.1016/j.ebiom.2017.10.005
- Shah MS, DeSantis TZ, Weinmaier T, et al. . Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. Gut 2018;67:882–91. 10.1136/gutjnl-2016-313189
- Lee JK, Liles EG, Bent S, et al. . Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160:171.
- Robertson DJ, Lee JK, Boland CR, et al. . Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task force on colorectal cancer. Gastroenterology 2017;152:1217–37. 10.1053/j.gastro.2016.08.053
- Yutin N, Galperin MY. A genomic update on clostridial phylogeny: gram-negative spore formers and other misplaced clostridia. Environ Microbiol 2013;140:2631–41. 10.1111/1462-2920.12173
- Traore SI, Azhar EI, Yasir M, et al. . Description of 'Blautia phocaeensis' sp. nov. and 'Lachnoclostridium edouardi' sp. nov., isolated from healthy fresh stools of Saudi Arabia Bedouins by culturomics. New Microbes New Infect 2017;19:129–31. 10.1016/j.nmni.2017.05.017
- Pham T-P-T, Cadoret F, Alou MT, et al. . 'Urmitella timonensis' gen. nov., sp. nov., 'Blautia marasmi' sp. nov., 'Lachnoclostridium pacaense' sp. nov., 'Bacillus marasmi' sp. nov. and 'Anaerotruncus rubiinfantis' sp. nov., isolated from stool samples of undernourished African children. New Microbes New Infect 2017;17:84–8. 10.1016/j.nmni.2017.02.004
- Tidjani Alou M, Khelaifia S, La Scola B, et al. . "Lachnoclostridium touaregense," a new bacterial species isolated from the human gut microbiota. New Microbes New Infect 2016;14:51–2. 10.1016/j.nmni.2016.07.007
- Zhang S, Cai S, Ma Y. Association between Fusobacterium nucleatum and colorectal cancer: progress and future directions. J Cancer 2018;9:1652–9. 10.7150/jca.24048
- Flanagan L, Schmid J, Ebert M, et al. . Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014;33:1381–90. 10.1007/s10096-014-2081-3
- Amitay EL, Werner S, Vital M, et al. . Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis 2017;38:781–8. 10.1093/carcin/bgx053
- Watanabe Y, Nagai F, Morotomi M, et al. . Bacteroides clarus sp. nov., Bacteroides fluxus sp. nov. and Bacteroides oleiciplenus sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2010;60:1864–9. 10.1099/ijs.0.015107-0
- Steer T, Collins MD, Gibson GR, et al. . Clostridium hathewayi sp. nov., from human faeces. Syst Appl Microbiol 2001;24:353–7. 10.1078/0723-2020-00044
- Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287–97. 10.1056/NEJMoa1311194
- Jalanka J, Salonen A, Salojärvi J, et al. . Effects of bowel cleansing on the intestinal microbiota. Gut 2015;64:1562–8. 10.1136/gutjnl-2014-307240
- Nakatsu G, Zhou H, Wu WKK, et al. . Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology 2018;155:529–41. 10.1053/j.gastro.2018.04.018
- Coker OO, Nakatsu G, Dai RZ, et al. . Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 2019;68:654–62. 10.1136/gutjnl-2018-317178
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754–60. 10.1093/bioinformatics/btp324
- Morgulis A, Gertz EM, Schäffer AA, et al. . A fast and symmetric dust implementation to mask low-complexity DNA sequences. J Comput Biol 2006;13:1028–40. 10.1089/cmb.2006.13.1028
- Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841–2. 10.1093/bioinformatics/btq033
- Franzosa EA, McIver LJ, Rahnavard G, et al. . Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 2018;15:962–8. 10.1038/s41592-018-0176-y
- Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014;30:2068–9. 10.1093/bioinformatics/btu153
- Wong SH, Kwong TNY, Chow T-C, et al. . Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut 2017;66:1441–8. 10.1136/gutjnl-2016-312766
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45. 10.2307/2531595
- Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>;2-3
Source: PubMed